Plasmin is essential in preventing periodontitis in mice.

Rima Sulniute,T. Lindh,M. Wilczyńska,Jinan Li,T. Ny

DOI: https://doi.org/10.1016/j.ajpath.2011.05.003

IF: 5.77

2011-08-01

American Journal Of Pathology

Abstract:

What problem does this paper attempt to address?

Quantum Dot-Pulsed Dendritic Cell Vaccines Plus Macrophage Polarization for Amplified Cancer Immunotherapy.

Feng Liu,Junlin Sun,Wenqian Yu,Qunying Jiang,Min Pan,Zhen Xu,Fengye Mo,Xiaoqing Liu

DOI: https://doi.org/10.1016/j.biomaterials.2020.119928

IF: 14

2020-01-01

Biomaterials

Abstract:Dendritic cell (DC) vaccines hold great potential in cancer immunotherapy, but the suboptimal design of DC vaccines and the immunosuppressive tumor microenvironment largely impair their anti-tumor efficacy. Here, quantum dot (QD) pulsed-DC vaccines integrating with tumor-associated macrophage polarization are developed for amplified anti-tumor immunity. Semiconductor QDs are engineered with diverse functions to act as fluorescence nanoprobes, immunomodulatory adjuvants, and nanocarriers to load tumor antigens and Toll-like receptor 9 agonists. The QD-pulsed DC vaccines enable spatiotemporal tracking of lymphatic drainage and efficacy evaluation of DC immunotherapy, and trigger potent immunoactivation. Specifically, designer DC vaccine plus macrophage polarization elicits potent immune response to stimulate innate and adaptive antitumor immunity and ameliorate the immunosuppressive tumor microenvironment. As a new combination therapy, this strategy greatly boosts antigen-specific T-cell immunity and thus strongly inhibits local tumor growth and tumor metastasis in vivo. This study may provide an applicable treatment for cancer immunotherapy.
Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors

Gun-Young Jang,Young Seob Kim,Sung Eun Lee,Ji won Lee,Hee Dong Han,Tae Heung Kang,Yeong-Min Park

DOI: https://doi.org/10.1007/s00262-020-02759-6

2020-10-28

Abstract:Cancer immunotherapy has fewer side effects and higher efficiency than conventional methods. Dendritic cell (DC)-based vaccine, a cancer immunotherapeutic, is prepared by processing mature DCs and pulsing with tumor antigen peptide ex vivo, to induce the activation of tumor-specific T lymphocytes followed by tumor clearance in vivo. Unfortunately, clinical trials of this method mostly failed due to low patient response, possibly due to the absence of novel adjuvants that induce DC maturation through Toll-like receptor (TLR) signals. Interestingly, immune checkpoint inhibitor (ICI) therapy has shown remarkable anti-tumor efficacy when combined with cancer vaccines. In this study, we identified 60S acidic ribosomal protein P2 (RPLP2) through pull-down assay using human cancer cells derived proteins that binds to Toll-like receptor 4 (TLR4). Recombinant RPLP2 induced maturation and activation of DCs in vitro. This DC-based vaccine, followed by pulsing with tumor-specific antigen, has shown to significantly increase tumor-specific CD8+IFN-γ+ T cells, and improved both tumor prevention and tumor treatment effects in vivo. The adjuvant effects of RPLP2 were shown to be dependent on TLR4 using TLR4 knockout mice. Moreover, ICIs that suppress the tumor evasion mechanism showed synergistic effects on tumor treatment when combined with these vaccines.

oncology,immunology
Tumor-repopulating cell-derived microparticles elicit cascade amplification of chemotherapy-induced antitumor immunity to boost anti-PD-1 therapy

Nana Bie,Tuying Yong,Zhaohan Wei,Qingle Liang,Xiaoqiong Zhang,Shiyu Li,Xin Li,Jianye Li,Lu Gan,Xiangliang Yang

DOI: https://doi.org/10.1038/s41392-023-01658-3

IF: 39.3

2023-10-25

Signal Transduction and Targeted Therapy

Abstract:Immune checkpoint blockade (ICB) therapy, particularly antibodies targeting the programmed death receptor 1 (PD-1) and its ligand (PD-L1), has revolutionized cancer treatment. However, its efficacy as a standalone therapy remains limited. Although ICB therapy in combination with chemotherapy shows promising therapeutic responses, the challenge lies in amplifying chemotherapy-induced antitumor immunity effectively. This relies on efficient drug delivery to tumor cells and robust antigen presentation by dendritic cells (DCs). Here, we developed tumor-repopulating cell (TRC)-derived microparticles with exceptional tumor targeting to deliver doxorubicin (DOX@3D-MPs) for improve anti-PD-1 therapy. DOX@3D-MPs effectively elicit immunogenic tumor cell death to release sufficient tumor antigens. Heat shock protein 70 (HSP70) overexpressed in DOX@3D-MPs contributes to capturing tumor antigens, promoting their phagocytosis by DCs, and facilitating DCs maturation, leading to the activation of CD8 + T cells. DOX@3D-MPs significantly enhance the curative response of anti-PD-1 treatment in large subcutaneous H22 hepatoma, orthotopic 4T1 breast tumor and Panc02 pancreatic tumor models. These results demonstrate that DOX@3D-MPs hold promise as agents to improve the response rate to ICB therapy and generate long-lasting immune memory to prevent tumor relapse.

biochemistry & molecular biology,cell biology
Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

Huan Yan,Guibin Lin,Zhanyan Liu,Fei Gu,Yuan Zhang

DOI: https://doi.org/10.1016/j.actbio.2023.02.034

IF: 10.633

2023-03-16

Acta Biomaterialia

Abstract:Immunostimulatory cues play an important role in priming antitumor immunity and promoting the efficacy of subunit cancer vaccines. However, the clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote vaccine efficacy, we develop vaccine formulations which integrate three key elements: (1) a nano-adjuvant formulated by conjugating an agonistic anti-CD40 monoclonal antibody (αCD40) to the surface of a polyIC-loaded lipid nanoparticle, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope that derived from a melanoma antigen gp100, (3) an agonistic anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In a syngeneic mouse model of melanoma, the vaccine formulations enhanced innate immunity and activated multiple innate immune signaling pathways within draining lymph nodes, as well as promoted antigen-specific immune responses and reduced immunosuppression in the tumor microenvironment, leading to profound tumor growth inhibition and prolonged survival. Thus, our vaccine formulations represent an attractive strategy to stimulate antitumor immunity and control tumor progression. Statement of significance The clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote the antitumor immunity of subunit vaccines, we develop novel vaccine formulations that integrate multifunctional modalities including (1) a nano-adjuvant containing anti-CD40 monoclonal antibody (αCD40) and TLR3 agonist which activate innate immunity through diverse signaling pathways, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope from tumor antigen, (3) an anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In this study, our vaccine formulations stimulate superior antitumor immunity and control tumor progression. The above nano-engineered platform and immunogenic biomacromolecules can be further applied to other T-cell-inducing vaccines.

engineering, biomedical,materials science, biomaterials
An 15N NMR study of the protonation of two di-(alpha-pyridyl) compounds in solutions and the solid state.

J. Klimkiewicz,L. Stefaníak,E. Grech,G. Webb,I. Wawer

DOI: https://doi.org/10.1016/S0926-2040(96)01253-2

IF: 2.812

1996-11-01

Solid State Nuclear Magnetic Resonance

Abstract:
Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens

Soodabeh Iranpour,Vahid Nejati,Nowruz Delirezh,Pouria Biparva,Sadegh Shirian

DOI: https://doi.org/10.1186/s13046-016-0444-6

2016-10-26

Abstract:BackgroundDeveloping safe and effective cancer vaccine formulations is a primary focus in the field of cancer immunotherapy. Dendritic cells (DC) are currently employed as cellular vaccine in clinical trials of tumor immunotherapy. Recognizing the critical role of DCs in initiating anti-tumor immunity has resulted in the development of several strategies that target vaccine antigens to DCs to trigger anti-tumor T cell responses. To increase the efficiency of antigen delivery systems for anti-tumor vaccines, encapsulation of tumor-associated antigens in polymer nanoparticles (NPs) has been established.MethodsIn this study, the effect of tumor lysate antigen obtained from three stage III breast cancer tissues encapsulated within PLGA NPs to enhance the DC maturation was investigated. The T-cell immune response activation was then fallowed up. Fresh breast tumors were initially used to generate tumor lysate antigens containing poly lactic-co-glycolic acid (PLGA) NP. The encapsulation efficiency and release kinetics were profiled. The efficiency of encapsulation was measured using Bradford protein assays measuring the dissolved NPs. The stability of released antigen from NPs was verified using SDS-PAGE. To evaluate the hypothesis that NPs enhances antigen presentation, including soluble tumor lysate, tumor lysate containing NPs and control NPs the efficiency of NP-mediated tumor lysate delivery to DCs was evaluated by assessing CD3+ T-cell stimulation after T cell/and DCs co-culture.ResultsThe rate of encapsulation was increased by enhancing the antigen concentration of tumor lysate. However, increasing the antigen concentration diminished the encapsulation efficiency. In addition, higher initial protein contenting NPs led to a greater cumulative release. All three patients released variable amounts of IFN-γ, IL-10, IL-12 and IL-4 in response to re-stimulation. T cells stimulated with lysate-pulsed DCs induced a substantial increase in IFN-γ and IL-12 production. We demonstrated that NPs containing tumor lysate can induce maturation and activation of DCs, as antigen alone does.ConclusionPLGA-NPs are attractive vehicles for protein antigen delivery which effectively induce stimulation and maturation of DCs, allowing not only an enhanced antigen processing and immunogenicity or improved antigen stability, but also the targeted delivery and slow release of antigens.

oncology
Coordinating Antigen Cytosolic Delivery and Danger Signaling to Program Potent Cross-Priming by Micelle-Based Nanovaccine

Zhida Liu,Chang Zhou,Yan Qin,Zihao Wang,Luyao Wang,Xiuli Wei,Yinjian Zhou,Qicheng Li,Hang Zhou,Wenjun Wang,Yang-Xin Fu,Mingzhao Zhu,Wei Liang

DOI: https://doi.org/10.1038/celldisc.2017.7

IF: 38.079

2017-01-01

Cell Discovery

Abstract:Although re-activating cytotoxic T-cell (CTLs) response inside tumor tissues by checkpoint blockade has demonstrated great success in tumor immunotherapy, active induction of efficient endogenous CTL response by therapeutic vaccines has been largely hampered by inefficient cytosolic delivery of antigens and coordinated activation of dendritic cells (DCs) in lymph nodes. Here we show that polyethylene glycol-phosphatidylethanolamine (PEG-PE) micelles transform soluble peptides into α-helix to enable their efficient cytosolic delivery. The same PEG-PE micelles also serve as chaperon of TLR4 signaling to coordinate its adjuvant effect on the same DCs. Furthermore, these nanovaccines effectively target lymph node DCs. Thus, PEG-PE micelle vaccines program at multiple key aspects for inducing strong CTL responses and build up a foundation for combinational tumor therapy.
Orchestrated codelivery of peptide antigen and adjuvant to antigen-presenting cells by using an engineered chimeric peptide enhances antitumor T-cell immunity

Haifeng Pan,Siyuan Yu,Haoyun Zhuang,Han Yang,Jinlu Jiang,Haihui Yang,Shuling Ren,Guoxing Luo,Xuan Yu,Shuping Chen,Yanhua Lin,Roufang Sheng,Shiyin Zhang,Quan Yuan,Chenghao Huang,Tianying Zhang,Tingdong Li,Shengxiang Ge,Jun Zhang,Ningshao Xia

DOI: https://doi.org/10.1158/2326-6066.cir-23-0926

IF: 10.1

2024-04-19

Cancer Immunology Research

Abstract:The intrinsic pharmacokinetic limitations of traditional peptide-based cancer vaccines hamper effective cross-presentation and codelivery of antigens and adjuvants, which are crucial for inducing robust antitumor CD8+ T-cell responses. Here, we report the development of a versatile strategy that simultaneously addresses the different pharmacokinetic challenges of soluble subunit vaccines composed of antigens and CpG to modulate vaccine efficacy via translating an engineered chimeric peptide, eTAT, as an intramolecular adjuvant. Linking antigens to eTAT enhanced cytosolic delivery of the antigens. This, in turn, led to improved activation and lymph node–trafficking of antigen-presenting cells and antigen cross-presentation, thus promoting antigen-specific T-cell immune responses. Simple mixing of eTAT-linked antigens and CpG significantly enhanced codelivery of antigens and CpG to the antigen-presenting cells, and this substantially augmented the adjuvant effect of CpG, maximized vaccine immunogenicity and elicited robust and durable CD8+ T-cell responses. Vaccination with this formulation altered the tumor microenvironment and exhibited potent antitumor effects, with generally further enhanced therapeutic efficacy when used in combination with anti-PD1. Altogether, the engineered chimeric peptide–based orchestrated codelivery of antigen and adjuvant may serve as a promising but simple strategy to improve the efficacy of peptide-based cancer vaccines.

oncology,immunology
A Three-In-One Assembled Nanoparticle Containing Peptide-Radio-Sensitizer Conjugate and TLR7/8 Agonist Can Initiate the Cancer-Immunity Cycle to Trigger Antitumor Immune Response

Xueqin Zhu,Xiaoxi Wang,Bingyu Li,Yun Zhang,Yalan Chen,Wenyan Zhang,Yan Wang,Wenjie Zhai,Zimai Liu,Sijia Liu,Jiaxin Sun,Zhenzhen Chen,Yanfeng Gao

DOI: https://doi.org/10.1002/smll.202107001

IF: 13.3

Small

Abstract:Radiotherapy (RT) has been shown to cause immunogenic cell death (ICD) of cancer cells, which promote the release of tumor-associated antigens, and trigger the cancer-immunity cycle (CIC). However, ICD induced by RT usually does not occur in hypoxic tumor cells due to their resistance to radiation. Moreover, RT also induces programmed death ligand 1 (PD-L1) upregulation on tumor cells, which has an inhibitory effect on T lymphocytes. Therefore, therapy based on CIC must selectively target the restricted steps of antitumor immunity. Herein, the authors design a versatile three-in-one assembling nanoparticle that can simultaneously execute these obstacles. The amphiphilic peptide drug conjugate NIA-D1, containing the hydrophobic radio-sensitizer 2-(2-nitroimidazol-1-yl) acetic acid (NIA), a peptide substrate of matrix metalloproteinase-2, and a hydrophilic PD-L1 antagonist D PPA-1, is constructed and co-assembled with hydrophobic Toll-like receptor (TLR) 7/8 agonist R848 to form nanoparticle NIA-D1@R848. The NIA-D1@R848 nanoparticles combined with RT can trigger the apoptosis of tumor cells and initiate the CIC. In the presence of R848, it promotes the maturation of dendritic cells, which together with protein programmed cell death protein 1 (PD-1) and its ligand PD-L1 blockade to relieve T cell suppression, and amplify the antitumor immune cycle. In conclusion, a functionalized three-in-one nanoparticle NIA-D1@R848 is successfully constructed, which can induce strong systemic antitumor immune response.
Self-assembly Nanovaccine Containing TLR7/8 Agonist and STAT3 Inhibitor Enhances Tumor Immunotherapy by Augmenting Tumor-Specific Immune Response.

Lele Zhang,Jiacheng Huang,Xiaona Chen,Caixu Pan,Yong He,Rong Su,Danjing Guo,Shengyong Yin,Shuai Wang,Lin Zhou,Jianxiang Chen,Shusen Zheng,Yiting Qiao

DOI: https://doi.org/10.1136/jitc-2021-003132

IF: 12.469

2021-01-01

Journal for ImmunoTherapy of Cancer

Abstract:BACKGROUND:Cancer vaccines are a promising strategy for cancer immunotherapy. Cancer vaccines elicits a specific cytotoxic immune response to tumor antigens. However, the efficacy of traditional peptide-based cancer vaccines is limited due to the inefficient delivery of antigens and adjuvants to dendritic cells (DCs). Therefore, it is necessary to develop a novel rationally designed cancer vaccine to maximize its desired effects.METHODS:A Self-assembling Vehicle-free Multi-component Antitumor nanoVaccine (SVMAV) was constructed by using an unsaturated fatty acid docosahexaenoic acid (DHA)-conjugated antigen and R848 (a Toll-like receptor 7/8 agonist) to encapsulate stattic (a signal transducer and activator of transcription 3 inhibitor). The characteristics of SVMAV were investigated. The ability of SVMAV to promote DC functions was examined by in vitro analysis. The antitumor effects of SVMAV and its combination with antiprogrammed cell death protein 1 antibody (aPD-1) were also investigated in vivo. The potential application of SVMAV for neoantigen-targeted, personalized cancer vaccines was examined in an orthotopic hepatocellular carcinoma model.RESULTS:The obtained SVMAV efficiently migrated into lymph nodes and primed CD8+ T cells for exert neoantigen-specific killing by promoting the antigen uptake by DCs, stimulating DC maturation, and enhancing antigen cross-presentation, due to the simultaneous delivery of the antigen, R848 and stattic. SVMAV could not only yield a robust antitumor effect for primary melanoma allografts, but also exert a protective effect for lung metastases. Moreover, combination treatment of SVMAV and aPD-1 exerted synergistic antitumor activity and extended the survival duration of melanoma-bearing mice. Notably, a cell line-specific neoantigen-based SVMAV was designed according to predicted neoantigens for Hepa1-6 cells to examine the potential application of SVMAV for personalized cancer vaccine. Encouragingly, neoantigen-specific SVMAV achieved stronger antitumor activity than aPD-1 in an orthotopic hepatocellular cancer model established with Hepa1-6 cells.CONCLUSIONS:In summary, this study offers an efficient codelivery platform for neoantigens and immunoregulatory compounds to enhance immune responses during cancer immune therapy.
Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy

Yuanwei Pan,Xianjia Wu,Lujie Liu,Chenchen Zhao,Jing Zhang,Shengren Yang,Pan Pan,Qinqin Huang,Xing-Zhong Zhao,Rui Tian,Lang Rao

DOI: https://doi.org/10.1002/adhm.202400068

Abstract:Cancer nanovaccines have attracted widespread attention by inducing potent cytotoxic T cell responses to improve immune checkpoint blockade (ICB) therapy, while the lack of co-stimulatory molecules limits their clinical applications. Here, a genetically engineered cancer cytomembrane nanovaccine is reported that simultaneously overexpresses co-stimulatory molecule CD40L and immune checkpoint inhibitor PD1 to elicit robust antitumor immunity for cancer immunotherapy. The CD40L and tumor antigens inherited from cancer cytomembranes effectively stimulate dendritic cell (DC)-mediated immune activation of cytotoxic T cells, while the PD1 on cancer cytomembranes significantly blocks PD1/PD-L1 signaling pathway, synergistically stimulating antitumor immune responses. Benefiting from the targeting ability of cancer cytomembranes, this nanovaccines formula shows an enhanced lymph node trafficking and retention. Compared with original cancer cytomembranes, this genetically engineered nanovaccine induces twofold DC maturation and shows satisfactory precaution efficacy in a breast tumor mouse model. This genetically engineered cytomembrane nanovaccine offers a simple, safe, and robust strategy by incorporating cytomembrane components and co-stimulatory molecules for enhanced cancer immunotherapy.
Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l -Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade

Yingying Hu,Lin Lin,Jie Chen,Kai Hao,Sijia Zhang,Xiaoya Guo,Zhaopei Guo,Huayu Tian,Xuesi Chen

DOI: https://doi.org/10.1021/acsami.0c12734

2020-08-18

Abstract:Weak T cell responses and immune checkpoints within tumors could be two key factors for limiting antitumor efficacy in the field of cancer immunotherapy. Thus, the combined strategy of tumor vaccines and immune checkpoint blockade has been widely studied and expected to boost antitumor immune responses. Herein, we first developed a two-barreled strategy to combine the nanovaccine with a gene-mediated PD-L1 blockade. On the one hand, polyethyleneimine (PEI) worked as a vaccine carrier to codeliver the antigen ovalbumin (OVA) and the adjuvant unmethylated cytosine-phosphate-guanine (CpG) to formulate the PEI/OVA/CpG nanovaccine through electrostatic binding, which realized both dendritic cell activation and antigen cross-presentation enhancement. On the other hand, the PD-L1 silence gene was loaded by PEI to form PEI/pshPD-L1 complexes, which were further in situ shielded by aldehyde-modified polyethylene glycol (OHC-PEG-CHO) via pH-responsive Schiff base bonds. The formed pshPD-L1@NPs could decrease PD-L1 expression on the tumor cells. However, such a combined two-barreled strategy improved feebly for tumor inhibition in comparison with monotherapy, exhibiting the antagonistic effect, which might be due to the limited T cell response enhancement in the tumor microenvironment. To solve this problem, we have further developed a three-barreled strategy to combine oral administration of l-arginine, which worked as an amplifier to induce robust T cell response enhancement, without causing the upregulation of other negative immune regulators. Superior antitumor behavior and tumor rechallenge protection were realized by the three-barreled strategy in B16F10-OVA (B16-OVA)-bearing mice. The unique three-barreled strategy we developed might offer a novel clinical therapeutic treatment.

materials science, multidisciplinary,nanoscience & nanotechnology
Blood Clot Scaffold Loaded with Liposome Vaccine and siRNAs Targeting PD-L1 and TIM-3 for Effective DC Activation and Cancer Immunotherapy

Yitong Chen,Yue Zhang,Beilei Wang,Qin Fan,Qianyu Yang,Jialu Xu,Huaxing Dai,Fang Xu,Chao Wang

DOI: https://doi.org/10.1021/acsnano.2c10797

IF: 17.1

2022-12-15

ACS Nano

Abstract:Tumor vaccines have been showing a relatively weak response rate in cancer patients, while deficiencies in delivery efficiency to dendritic cells (DCs), as well as DC-intrinsic immunosuppressive signals, contribute to a great extent. In this work, we report an implantable blood clot loaded with liposomes-protamine-hyaluronic acid nanoparticles (LPH NPs) containing vaccine (LPH-vaccine) and LPH NPs containing siRNA (LPH-siRNA) for synergistic DC recruitment and activation. The subcutaneously implanted blood clot scaffold can recruit abundant immune cells, particularly DCs, to form a DC-rich environment in vivo. Within the scaffold, LPH-vaccine effectively delivers antigens and adjuvants to the recruited DCs and induces the maturation of DCs. More importantly, LPH-siRNA that targets programmed death-ligand 1 (PD-L1) and T cell immunoglobulin and mucin-containing molecule 3 (TIM-3) can reduce immunosuppressive signals in mature DCs and prevent the DCs from expressing a regulatory program in the scaffold. The activated DCs correlate with an improved magnitude and efficacy of T cell priming, resulting in the production of tumor antigen-specific T cells in multiple mouse models. Our strategy can also be used for patient-tailored therapy by change of tumor neoantigens, suggesting a promising strategy for cancer therapy in the clinic.

materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology
Polymersomal Poly(I:C) Self‐Magnifies Antitumor Immunity by Inducing Immunogenic Cell Death and Systemic Immune Activation

Jingyi Wang,Beibei Guo,Zhiwei Sun,Songsong Zhao,Li Cao,Zhiyuan Zhong,Fenghua Meng

DOI: https://doi.org/10.1002/adhm.202400784

IF: 10

2024-06-21

Advanced Healthcare Materials

Abstract:Immunotherapy has emerged as a powerful weapon against lung cancer, yet only a fraction of patients respond positively to the treatment. Poly(I:C) effectively triggers both innate and adaptive immunity. It is also capable of inducing immunogenic cell death (ICD) in tumor cells. However, its efficacy is hindered by its instability in vivo and limited cellular uptake. To address this, we encapsulated poly(I:C) in cRGD‐targeted polymersomes (t‐PPIC), which significantly increased its stability and uptake, resulting in the vital activation of dendritic cells (DCs) and apoptosis of lung tumor cells in vitro. In a murine LLC lung tumor model, systemic administration of t‐PPIC effectively suppressed tumor growth and led to striking survival benefits, with 40% of the mice becoming tumor‐free. Notably, t‐PPIC provoked stronger apoptosis and ICD in tumor tissue and elicited a more potent stimulation of DCs, recruitment of NK cells, and activation of CD8+ T cells, compared to free poly(I:C) and nontargeted PPIC controls. Furthermore, when combined with immune checkpoint inhibitors or radiotherapy, t‐PPIC amplified the antitumor immune response, resulting in complete regression in 60% of the mice. These compelling findings underscore the potential of integrin‐targeted polymersomal poly(I:C) to enhance antitumor immunity by simultaneously inducing ICD and systemic immune activation. This article is protected by copyright. All rights reserved

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model

Zhibing Lin,Yan Zhang,Huaman Cai,Fuqiang Zhou,Hongjun Gao,Li Deng,Rongxiu Li

DOI: https://doi.org/10.1016/j.omto.2019.06.002

2019-09-01

Abstract:Engagement of programmed death 1 receptor (PD-1) and its ligand PD-L1/2 induces a signal transduction pathway that inhibits the activity of tumor infiltrating cytotoxic T lymphocytes, and promotes tumor growth and metastasis. Antibodies blocking PD-1 or PD-L1 can restore antitumor T cell responses and cause long-term remissions in a subset of cancer patients with advanced or refractory tumors. In this study, we ask whether PD-L1 vaccination could confer tumor control in mouse tumor models. To address the central tolerance towards self-molecules, we fused the extracellular domain of PD-L1 (PD-L1E) to the C-terminal of the translocation domain of diphtheria toxin (DTT). DTT is able to elicit CD4+ T cell responses required for inducing robust immune responses against self-molecules. The fusion molecule is named as DPDL1E. When formulated with incomplete Freund's adjuvant (IFA), DPDL1E elicited robust immune responses biased towards Th1 type, and inhibited tumor growth in both preventive and therapeutic mouse tumor models. We further showed that the anti-DPDL1E sera blocked PD-L1 binding to PD-1 in vitro. The DPDL1E vaccination increased the levels of tumor infiltrating T cells (TIL) and reduced the levels of myeloid-derived suppressor cells (MDSCs) as well as exhausted LAG3+PD-1+ CD8+ T cells. All data suggests that DPDL1E vaccination reverts the suppressive phenotype of tumor microenvironment and is a promising strategy for cancer therapy.
Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy

Zhaoyuan Liang,Xinyue Cui,Liqun Yang,Qin Hu,Danyang Li,Xiaofei Zhang,Lu Han,Siwei Shi,Yurong Shen,Weijian Zhao,Qi Ju,Xiongwei Deng,Yan Wu,Wang Sheng

DOI: https://doi.org/10.1016/j.ijpharm.2021.121091

IF: 6.51

2021-10-01

International Journal of Pharmaceutics

Abstract:Cancer vaccines targeting tumor specific neoantigens derived from nonsynonymous mutations of tumor cells have emerged as an effective approach to induce antitumor T cells responses for personalized cancer immunotherapy. Despite the enormous potential of synthetic peptides as a common modality for neoantigen vaccines, their practical efficacy was limited due to their relatively low immunogenicity. Herein, we modify neoantigen peptide (Adpgk) derived from MC-38 colon carcinoma by supplementing ten consecutive positively-charged lysines (10 K-Adpgk) to obtain cationic polypeptide. And then we made them self-assemble with toll-like receptor 9 (TLR-9) agonist CpG oligodeoxynucleotides (CpG ODN) adjuvant directly forming antigen/adjuvant integrated nanocomplexes (PCNPs) through electrostatic interaction for potent tumor immunotherapy. The optimal formed PCNPs were around 175 nm with uniform size distribution and could maintain stability in physiological saline solution. CpG ODN and 10 K-Adpgk in the formed PCNPs could be effectively uptake by dendritic cells (DCs) and stimulate the maturation of DCs as well as improving the efficiency of antigen cross-presentation efficiency in vitro. Furthermore, the PCNPs vaccine could markedly improve neoantigen and adjuvant co-delivery efficiency to lymphoid organs and activate cytotoxic T cells. In addition, vaccination with PCNPs could not only offer prophylactic to protect mice from challenged MC-38 colorectal tumors, but also achieve a better anti-tumor effect in an established colorectal tumor model, and significantly prolong the survival rate of tumor-bearing mice. Therefore, this work provided a versatile but effective method for neoantigen peptide and CpG ODN co-assembly vaccine platform for efficient colorectal cancer immunotherapy.

pharmacology & pharmacy
A Dual Enhancing Strategy of Novel Nanovaccine Based on TIM3 Silencing Nanoadjuvants and Desialylated Cancer Cell Membrane Antigens for Personalized Vaccination Immunotherapy of Cancer

Kaiming Li,Xiaolin Li,Jie Wu,Haisi Wu,Min Wu,Yupeng Zhou,Ya Lin,Yifan Zou,Xiqun Jiang,Huae Xu

DOI: https://doi.org/10.1002/adfm.202404956

IF: 19

2024-06-27

Advanced Functional Materials

Abstract:A novel nanovaccine (dClip‐LNP/siRNA) based on T‐cell immunoglobulin and mucin‐domain containing‐3 (TIM3) silencing and Toll‐like receptors (TLRs) activation nanoadjuvant (LNP/siRNA) and desialylated cancer cell membrane antigens (dClip) is developed. This nanovaccine effectively promotes dendritic cell (DC) maturation and activation while providing tumor antigens. Importantly, the nanovaccine significantly activates anti‐tumor immune responses, leading to the suppression of tumor growth and prevention of tumor occurrence. Cancer vaccines represent a promising form of immunotherapy employed in the treatment of cancer. However, their efficiency in eliciting immune responses is limited, and satisfactory results have yet to be achieved. Optimizing adjuvants and antigens is an important approach to promoting the anti‐tumor efficacy of cancer vaccines. Here, a novel nanoadjuvant (LNP/siRNA) designed to silence T‐cell immunoglobulin and mucin‐domain containing‐3 (TIM3) and activate Toll‐like receptors (TLRs) is presented. The LNP/siRNA demonstrates significant potential in promoting dendritic cell (DC) maturation and enhancing the anti‐tumor response. Furthermore, desialylated cancer cell membrane is utilized as antigens, providing a variety of tumor antigens for DCs and enhancing their function. Additionally, they are integrated to create a core‐shell structured nanovaccine (dClip‐LNP/siRNA) through coextrusion, which collectively enhances the cross‐presentation ability of DCs, thus achieving a dual enhancement strategy. The dClip‐LNP/siRNA significantly silences TIM3 expression in DCs and promotes antigen presentation by DCs. Besides, dClip‐LNP/siRNA significantly promotes the activation of T cells in lymph nodes and induces robust and durable anti‐tumor immunity in tumor sites to eliminate established B16‐OVA tumors, prevent tumor occurrence, and suppress tumor lung metastasis. The dClip‐LNP/siRNA is also suitable for combination with adoptive OT‐I cell therapy to enhance cancer immunotherapy. The dClip‐LNP/siRNA represents a robust vaccine platform for personalized cancer immunotherapy.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Antigen‐Capturing Dendritic‐Cell‐Targeting Nanoparticles for Enhanced Tumor Immunotherapy Based on Photothermal‐Therapy‐Induced in‐situ Vaccination

Yingmin Li,Yang Luo,Lamei Hou,Zhengjie Huang,Yi Wang,Shaobing Zhou

DOI: https://doi.org/10.1002/adhm.202202871

IF: 10

2023-06-06

Advanced Healthcare Materials

Abstract:In‐situ vaccines have revolutionized immunotherapy as they can stimulate tumor‐specific immune responses, with the cancer being the antigen source. However, the heterogeneity of tumor antigens and insufficient dendritic cell (DC) activation result in low cancer immunogenicity and hence poor vaccine response. Here, we designed a new in‐situ vaccine composed of acid‐responsive liposome‐coated polydopamine (PDA) nanoparticles modified with mannose and loaded with resiquimod (R848) to promote the efficacy of immunotherapy. The in‐situ vaccine can actively target the tumor site based on the decomposition of the liposome, while the PDA nanoparticles promote photothermal therapy and capture the immunogenic cell‐death‐induced tumor‐associated antigens based on the adsorption effect of dopamine‐mimetic mussels. The PDA nanoparticles, which were modified with a mannose ligand, target the DCs and release R848 for activated antigen presentation. As a result, the in‐situ vaccine not only effectively activates the maturation of the DCs but also significantly enhances their effect on cytotoxic T lymphocyte cells. Furthermore, the vaccine effectively inhibits the distant recurrence and metastasis of tumors via long‐term immune memory effects. Therefore, the in‐situ vaccine provides a potential strategy for improving the efficacy of cancer immunotherapy. This article is protected by copyright. All rights reserved

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
Combinational delivery of TLR4 and TLR7/8 agonist enhanced the therapeutic efficacy of immune checkpoint inhibitors to colon tumor

Mengjiao Wang,Quan Wan,Chenglv Wang,Qianyu Jing,Yujie Nie,Xiangyan Zhang,Xin Chen,De Yang,Runsang Pan,Linzhao Li,Lan Zhu,Huan Gui,Shuanghui Chen,Yuezhen Deng,Tao Chen,Yingjie Nie

DOI: https://doi.org/10.1007/s11010-024-04966-6

IF: 3.842

2024-03-21

Molecular and Cellular Biochemistry

Abstract:Immunotherapy is regarded as a potent cancer treatment, with DC vaccines playing a crucial role. Although clinical trials have demonstrated the safety and efficacy of DC vaccines, loading antigens in vitro is challenging, and their therapeutic effects remain unpredictable. Moreover, the diverse subtypes and maturity states of DCs in the body could induce both immune responses and immune tolerance, potentially affecting the vaccine's efficacy. Hence, the optimization of DC vaccines remains imperative. Our study discovered a new therapeutic strategy by using CT26 and MC38 mouse colon cancer models, as well as LLC mouse lung cancer models. The strategy involved the synergistic activation of DCs through intertumoral administration of TLR4 agonist high-mobility group nucleosome binding protein 1 (HMGN1) and TLR7/8 agonist (R848/resiquimod), combined with intraperitoneal administration of TNFR2 immunosuppressant antibody. The experimental results indicated that the combined use of HMGN1, R848, and α-TNFR2 had no effect on LLC cold tumors. However, it was effective in eradicating CT26 and MC38 colon cancer and inducing long-term immune memory. The combination of these three drugs altered the TME and promoted an increase in anti-tumor immune components. This may provide a promising new treatment strategy for colon cancer.

cell biology
Self-assembled nanospheres mediate phototherapy and deliver CpG oligodeoxynucleotides to enhance cancer immunotherapy of breast cancer and melanoma

Guohui Yu,Fan Dong,Wenshu Ge,Lisha Sun,Ludan Zhang,Lintian Yuan,Ningyu Li,Hao Dai,Lei Shi,Yuguang Wang

DOI: https://doi.org/10.1016/j.nantod.2022.101498

IF: 17.4

2022-01-01

Nano Today

Abstract:In the tumor microenvironment (TME) in certain cancer patients, the lack of tumor-associated antigens (TAAs) and low antigen presentation ability of antigen-presenting cells (APCs) limit the systemic immune effect of immune checkpoint blockade (ICB) therapy, which fails to elicit a persistent immune response. In this study, we used an important immune adjuvant (CpG ODN) and a photosensitizer (ICG) with 808 nm laser irradiation to trigger photodynamic and photothermal responses to synthesize intertwining DNA-photosensitizer nanosphere (iDP-NS) that can resolve the aforementioned shortcomings of current therapies and, together with programmed cell death-ligand 1 (PD-L1) treatment, convert uninflamed “cold” tumors into “hot” tumors. Hybrid nanosphere-mediated dual-modality photothermal/photodynamic therapy can be used to release TAAs and deliver immunostimulatory CpG ODNs to dendritic cells. In this approach, enhanced antigen presentation and immune checkpoint blockade therapy synergistically reinitiate toxic T cell activity and amplify immune effects, which can produce a powerful immune response and eliminate tumors in breast cancer and melanoma animal models. Notably, we proved that iDP-NSs mediated photo-immune response combined with ICB therapy can effectively trigger long immune memory to inhibit tumor recurrence and metastasis in 4T1 postoperative model.

Plasmin is essential in preventing periodontitis in mice.

Quantum Dot-Pulsed Dendritic Cell Vaccines Plus Macrophage Polarization for Amplified Cancer Immunotherapy.

Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors

Tumor-repopulating cell-derived microparticles elicit cascade amplification of chemotherapy-induced antitumor immunity to boost anti-PD-1 therapy

Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

An 15N NMR study of the protonation of two di-(alpha-pyridyl) compounds in solutions and the solid state.

Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens

Coordinating Antigen Cytosolic Delivery and Danger Signaling to Program Potent Cross-Priming by Micelle-Based Nanovaccine

Orchestrated codelivery of peptide antigen and adjuvant to antigen-presenting cells by using an engineered chimeric peptide enhances antitumor T-cell immunity

A Three-In-One Assembled Nanoparticle Containing Peptide-Radio-Sensitizer Conjugate and TLR7/8 Agonist Can Initiate the Cancer-Immunity Cycle to Trigger Antitumor Immune Response

Self-assembly Nanovaccine Containing TLR7/8 Agonist and STAT3 Inhibitor Enhances Tumor Immunotherapy by Augmenting Tumor-Specific Immune Response.

Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy

Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l -Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade

Blood Clot Scaffold Loaded with Liposome Vaccine and siRNAs Targeting PD-L1 and TIM-3 for Effective DC Activation and Cancer Immunotherapy

Polymersomal Poly(I:C) Self‐Magnifies Antitumor Immunity by Inducing Immunogenic Cell Death and Systemic Immune Activation

A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model

Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy

A Dual Enhancing Strategy of Novel Nanovaccine Based on TIM3 Silencing Nanoadjuvants and Desialylated Cancer Cell Membrane Antigens for Personalized Vaccination Immunotherapy of Cancer

Antigen‐Capturing Dendritic‐Cell‐Targeting Nanoparticles for Enhanced Tumor Immunotherapy Based on Photothermal‐Therapy‐Induced in‐situ Vaccination

Combinational delivery of TLR4 and TLR7/8 agonist enhanced the therapeutic efficacy of immune checkpoint inhibitors to colon tumor

Self-assembled nanospheres mediate phototherapy and deliver CpG oligodeoxynucleotides to enhance cancer immunotherapy of breast cancer and melanoma